Skip to main content
SpringerLink
Log in

Dosing of thioTEPA for myeloablative therapy

  • Original Article
  • ThioTEPA, Bone Marrow Transplantation, Pharmacokinetics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

High-dose thioTEPA is used frequently in myeloablative regimens for marrow transplantation, but the need for dose adjustments in obese patients has not been explored. We determined the pharmacokinetics of thioTEPA and its metabolite TEPA during first-dose infusion of thioTEPA 150–250 mg/m2 given daily for 3 days in combination with busulfan and cyclophosphamide, and evaluated the results for correlations with toxicity and dosing strategies. The study included 15 adults undergoing marrow transplantation for hematologic malignancies. Plasma samples were obtained at various times over a 24-h period, and concentrations of thio TEPA and TEPA were measured by gas chromatography. At 22–24 h after initiation of a 4-h infusion, the mean ±SE plasma concentration of thioTEPA was 124±63 ng/ml, while that of TEPA was 235±69 ng/ml. For CFU-GM and BFU-E growth in vitro, the IC50s of thioTEPA were 83 ng/ml and 16 ng/ml, respectively, and the IC50s of TEPA were 141 ng/ml and 47 ng/ml, respectively. Using a twocompartment model, the mean thioTEPA Vc was 47.4±4.7 l/m2, t1/2α 19±5 min,t 1/2β 3.7±0.5 h, and plasma clearance 302±21 ml/min per m2. The mean AUCs were 6.9–16.2 mg h/l for thioTEPA and 8.9–21.2 mg h/l for TEPA, while the mean peak concentrations were 0.95–2.08 μg/ml for thioTEPA and 0.88–1.90 μg/ml for TEPA. There was a significant association of grades 2–4 maximum regimen-related toxicity (RRT) with TEPA peak >1.75 μg/ml and with combined thioTEPA and TEPA AUC >30 mgh/l (5/6 vs 0/9,P=0.01 for both comparisons), suggesting that drug exposure was an important determinant of toxicity and, potentially, efficacy. ThioTEPA Vc correlated best with adjusted body weight (r=0.74,P=0.0015). In an evaluation of 74 adults receiving thioTEPA 750 mg/m2 in combination with busulfan and cyclophosphamide, the maximum RRT for patients at ideal weight was significantly greater than that for obese patients dosed on ideal weight (mean RRT grade 1.7 vs 1.0,P=0.004) but did not differ from the maximum RRT for obese adults dosed on actual or adjusted weights. We recommend that for obese patients thioTEPA be dosed on adjusted body weight. Measurements at time-points after 24 h are needed to determine when thioTEPA and TEPA concentrations are below myelosuppressive levels and safe for marrow infusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, Bitran JD (1988) Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol 6:1192

    Google Scholar 

  2. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA, Schnipper LE, Frei E (1990) High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol 17 [Suppl 3]:33

    Google Scholar 

  3. Bateman JC (1955) Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med 252:879

    Google Scholar 

  4. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562

    Google Scholar 

  5. Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL (1986) Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat Rep 70:859

    Google Scholar 

  6. Cox J, Penn N, Masood M, Hancock AK, Parker D (1987) Drug overdose—a hidden hazard of obesity. J R Soc Med 80:87

    Google Scholar 

  7. Devine BJ (1974) Gentamicin therapy. Drug Intell Clin Pharmacol 8:650

    Google Scholar 

  8. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra S, Van Besien K, Delasalle KB, Reading C, Deisseroth AB, Champlin RE (1993) Thiotepa, busulfan and cyclophosphamide: A new preparative regimen for autologous marrow or peripheral blood stem cells transplantation in high risk multiple myeloma. Blood 82:2324

    Google Scholar 

  9. Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E, Antman K (1990) A Phase I–II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 8:1239

    Google Scholar 

  10. Hagen B (1991) Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects. Cancer Chemother Pharmacol 27:373

    Google Scholar 

  11. Hagen B, Walseth F, Walstad RA, Iversen T, Nilsen OG (1987) Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma. Cancer Chemother Pharmacol 19:143

    Google Scholar 

  12. Hagen B, Walstad RA, Nilsen OG (1988) Pharmacokinetics of thio-TEPA at two different doses. Cancer Chemother Pharmacol 22:356

    Google Scholar 

  13. Hagen B, Neverdal G, Walstad RA, Nilsen OG (1990) Longterm pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients. Cancer Chemother Pharmacol 25:257

    Google Scholar 

  14. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singher LJ, Ettinger LJ, Gillespie A, Sam J, Poplack D (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: Evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49:736

    Google Scholar 

  15. Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K (1987) Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep 71: 1043

    Google Scholar 

  16. Lazarus H, Reed M, Spitzer T, Rabaa M, Blumer J (1987) High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71:789

    Google Scholar 

  17. Leonard BJ, Israels MCG, Wilkinson JF (1956) Treatment of Hodgkin's granuloma, chronic lymphatic leukemia, polycythemia vera and other reticuloses with triethylene-thiophosphoramide. Lancet i:1017

    Google Scholar 

  18. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25:139

    Google Scholar 

  19. McDermott BJ, Double JA, Bibby MC Wilman DEV, Loadman PM, Turner RL (1985) Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens. J Chromatogr Biomed Appl 338:335

    Google Scholar 

  20. Mosteller RD (1987) Simplified calculation of body-surface area. New Engl J Med 317:1098

    Google Scholar 

  21. Ng S-F, Waxman DJ (1990) biotransformation of N, N′, N′'-triethylenethiophosphoramide: oxidative desulfuration to yield N, N′, N′'-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. Cancer Res 50:464

    Google Scholar 

  22. Ng S-F, Waxman DJ (1991) N, N′, N′'-Triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. Cancer Res 51:2340

    Google Scholar 

  23. Notari RE (1987) Biopharmaceuticals and clinical pharmacokinetics. Marcel Dekker, New York Basel, p. 380

    Google Scholar 

  24. O'Dwyer PJ, LaCreta F, Engstrom PF, Peter R, Tartaglia L, Cole D, Litwin S, DeVito J, Poplack D, DeLap RJ, Comis RL (1991) Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res 51:3171

    Google Scholar 

  25. O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF (1992) Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 10:1352

    Google Scholar 

  26. Petros WP, Madden T, Gupton C, Egorin MJ, Fangmeier J, Peters WP (1994) Dose-related clearance of thiotepa in patients receiving high-dose chemotherapy and autologous bone marrow transplantation. Pharmacotherapy 14:361

    Google Scholar 

  27. Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219

    Google Scholar 

  28. Przepiorka D, Dimopoulos M, Smith T, Ippoliti C, Diener K, Luna M, Alexanian R, Champlin RE (1994) Thiotepa, busulfan and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicities. Ann Hematol 68:183

    Google Scholar 

  29. Przepiorka D, Ippoliti C, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, Estey E, Andreeff M, Champlin R (1994) A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 14:449

    Google Scholar 

  30. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, van Besien K, Andersson B, Deisseroth AB, Luna M, Cabanillas F, Champlin R (1995) A phase I–II study of high-dose thiotepa, busulfan and cyclophosphamide as a transplant regimen for malignant lymphoma. Leuk Lymphoma (in press)

  31. Williams SF, Bitran JD, Kaminer L, Westbrook C, Jacobs R, Ashenhurst J, Robin E, Purl S, Beschorner J, Schroeder C, Golomb HM (1987) A phase I–II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol 5:260

    Google Scholar 

  32. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D, Stranjord S, Giannone L, Coccia P, Weick JL, Rothman SA, Krupp KR, Lowder J, Bolwell B, Herzig GP (1990) High-dose N, N′, N′'-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 17: (Suppl 3): 2

    Google Scholar 

  33. Zuccaro P, Guandalini S, Pacifici R, Pichini S, Di Martino L, Guiducci M, Guiliani M, Di Tullio MT, Pettoello-Mantovani M (1991) Fat body mass and pharmacolinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monitor 13:37

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Universityof Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA

    Donna Przepiorka, Cindy Ippoliti & Meletios Dimopoulos

  2. Department of Experimental Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Timothy Madden

  3. Departmental of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Zeev Estrov

Authors
  1. Donna Przepiorka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Madden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cindy Ippoliti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zeev Estrov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meletios Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by a grant from the American Cyanamid Corporation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Przepiorka, D., Madden, T., Ippoliti, C. et al. Dosing of thioTEPA for myeloablative therapy. Cancer Chemother. Pharmacol. 37, 155–160 (1995). https://doi.org/10.1007/BF00685643

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685643

Key words

Search

Navigation